<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Asthma.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;University of Michigan Health System. Asthma. Ann Arbor (MI): University of Michigan Health System; 2010 Mar. 25 p.  [2 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: University of Michigan Health System. Asthma. Ann Arbor (MI): University of Michigan Health System; 2006 Feb. 16 p. [15 references]&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Asthma, unspecified type, unspecified  (493.90); General physical examination  (89.7)"/><FieldValue Value="MSH: Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Anti-Asthmatic Agents ; Asthma ; Breast Feeding ; Bronchial Spasm ; Bronchodilator Agents ; Diagnosis, Differential ; Immunization ; Leukotriene Antagonists ; Medical History Taking ; Patient Care Planning ; Patient Education as Topic ; Peak Expiratory Flow Rate ; Physical Examination ; Pregnancy ; Referral and Consultation ; Respiratory Function Tests ; Severity of Illness Index ; Spirometry "/><FieldValue Value="MTH: Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Asthma ; Asthma, unspecified type, without mention of status asthmaticus ; Breast Feeding ; Differential Diagnosis ; follow-up ; Immunization ; Inhaler ; Leukotriene Antagonists ; Mast cell stabilizer ; methylxanthine ; Patient education (procedure) ; Peak expiratory flow rate measurement ; physical examination ; Pregnancy ; Respiratory Function Tests ; Spirometer (device) "/><FieldValue Value="SNOMEDCT_US: Antiasthmatic agent  (360253007); Asthma  (195967001); Asthma trigger  (400987003); Beta-adrenoceptor agonist  (349920008); Beta-adrenoceptor agonist  (373227004); Breast fed  (169741004); Bronchodilator  (353866001); Bronchodilator  (372580007); Bronchospasm  (4386001); Corticoid preparation  (21568003); Corticoid preparation  (79440004); Differential diagnosis  (47965005); Education of caregiver  (427519008); Education of caregiver  (460617003); Immunization  (127785005); Inhaler  (334980009); Inhaler  (420317006); Leukotriene receptor inhibitor  (108616001); Leukotriene receptor inhibitor  (372517002); Mast cell stabilizer  (108860003); Mast cell stabilizer  (372553000); Measurement of respiratory function  (23426006); Methyl xanthine  (259553003); Patient education  (311401005); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Pregnancy  (289908002); Spirometer  (303501006); Spirometry  (127783003)"/><FieldValue Value="UMD: Inhalers, Aerosol  (12-128); Spirometers  (13-674)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Asthma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Allergy and Immunology" /><FieldValue Value="Critical Care" /><FieldValue Value="Emergency Medicine" /><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nursing" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Pediatrics" /><FieldValue Value="Pharmacology" /><FieldValue Value="Pulmonary Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Respiratory Care Practitioners" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide evidence-based guidance to improve the patient's quality of life by controlling asthma symptoms at rest and during exercise, attaining normal lung function, and minimizing adverse drug reactions; preventing exacerbations; attaining normal activity levels, including exercise; and preventing unscheduled office visits, emergency visits, hospitalizations, and premature death&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Children, adolescents, and adults with asthma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Evaluation/Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Physical examination and patient history (to determine if symptoms and signs of asthma are present) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Trial of reversibility using a short acting beta-agonist (SABA) in appropriate populations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lung function testing (spirometry) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exclusion of alternative diagnoses &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of asthma severity &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Education of patients and care givers including&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Asthma mechanisms: inflammation and bronchospasm &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The Asthma Action Plan (AAP) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Triggers, environmental exposures &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Proper inhaler and device use &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Warning symptoms/signs &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Peak expiratory flow rate (PEFR) if indicated &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Controller vs. rescue medications &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoidance or control of asthma triggers&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Environmental tobacco smoke &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Indoor allergens &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Outdoor allergens &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Food triggers &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Indoor air pollution &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Exercise-induced bronchospasm (EIB) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Infections &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Concurrent medical conditions &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initiation of medical therapy in a stepwise approach&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Short-acting beta agonists (SABAs) [bronchodilator] &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Inhaled corticosteroids (ICSs) [anti-inflammatory] &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Long-acting beta agonists (LABAs) [bronchodilator] &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Leukotriene receptor antagonists (LTRAs) [anti-inflammatory] &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Mast cell stabilizers and/or methylxanthines [anti-inflammatory] &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Systemic (oral) corticosteroids [anti-inflammatory] &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pediatric considerations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of related comorbidities &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Peak expiratory flow rate (PEFR) monitoring &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ongoing management including immunizations, follow-up, and referral, when appropriate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Special circumstances (e.g., pregnancy and breastfeeding, surgery) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Complementary/alternative therapies were considered, but not deemed beneficial in asthma.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Symptom relief &lt;/li&gt;&#xA;    &lt;li&gt;Patient quality of life &lt;/li&gt;&#xA;    &lt;li&gt;Drug interactions and side effects &lt;/li&gt;&#xA;    &lt;li&gt;Asthma associated morbidity and mortality &lt;/li&gt;&#xA;    &lt;li&gt;Peak expiratory flow rate (PEFR) &lt;/li&gt;&#xA;    &lt;li&gt;Occurrence of rescue beta-agonist use &lt;/li&gt;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The team began the search of literature by accepting the results of the literature search performed for the National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, July 2007. That group systematically reviewed evidence published through March 15, 2006.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;To update that search with more recent literature, a systematic search of literature on Medline was performed for the period from 1/1/06 through 1/30/08. The major search term was asthma and the search was performed for literature on humans (adult and pediatric) in the English language. Searches were performed on the following specific topics.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diagnosis and: history (rhinitis, nasal polyps, atopic dermatitis); physical exam, signs, symptoms (normal, wheezing, intercostal retraction during inspiration, chest hyperinflation, prolonged expiratory phase); spirometry; and other references to diagnosis. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment and: disease management programs; self management (including action plan and patient education); objective assessment (peak expiratory flow rate [PEFR] monitoring); avoid, control triggers (smoking, allergens, foods, indoor air pollution, medications, exercise, concurrent medical conditions, environmental control); pharmacotherapy; adverse effects of pharmacotherapy; complementary alternative, and integrative medicine; follow up, consultation, referral; pregnancy, other references to treatment or management. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other references not associated with diagnosis or treatment. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The search was conducted in components each keyed to a specific causal link in a formal problem structure (available upon request). The search was supplemented with very recent clinical trials known to expert members of the panel. Negative trials were specifically sought. The search was a single cycle.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Conclusions were based on prospective randomized controlled trials (RCTs) if available, to the exclusion of other data; if randomized controlled trials (RCTs) were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The &quot;strength of recommendation&quot; for key aspects of care was determined by expert opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;I = Generally should be performed&lt;/p&gt;&#xD;&#xA;&lt;p&gt;II = May be reasonable to perform&lt;/p&gt;&#xD;&#xA;&lt;p&gt;III = Generally should not be performed&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Drafts of this guideline were reviewed in clinical conferences and by distribution for comment within departments and divisions of the University of Michigan Medical School to which the content is most relevant: Allergy, Emergency Medicine, Family Medicine, General Medicine, General Pediatrics, Geriatric Medicine, Obstetrics &amp;amp; Gynecology (Women's Health), Pediatric Pulmonology, and Pulmonary &amp;amp; Critical Care Medicine. The Executive Committee for Clinical Affairs of the University of Michigan Hospitals and Health Centers endorsed the final version.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;em&gt;Note from the University of Michigan Health System (UMHS) and the National Guideline Clearinghouse (NGC)&lt;/em&gt;&lt;/strong&gt;: The following guidance was current as of March 2010. Because UMHS occasionally releases minor revisions to its guidance based on new information, users may wish to consult the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/asthma.html&quot; title=&quot;UMHS Web site&quot;&gt;original guideline document&lt;/a&gt; for the most current version.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Note from NGC&lt;/strong&gt;: The following key points summarize the content of the guideline. Refer to the full text for additional information, including detailed information on diagnosis of asthma, initial and ongoing asthma management, and special circumstances.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The levels of evidence [A-D] and the strength of recommendation [I-III] are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Key Points&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;A high index of suspicion&lt;/strong&gt; for asthma is essential. A history of both symptoms and symptom triggers should be obtained. &lt;em&gt;[IC]&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Diagnosis&lt;/strong&gt; is &lt;em&gt;clinical&lt;/em&gt; in young children and may include &lt;em&gt;both&lt;/em&gt; clinical features and lung function test results in older children and adults &lt;em&gt;[IC]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Objective evaluation of airflow obstruction&lt;/strong&gt; (spirometry) should be used&amp;nbsp;in the diagnosis, classification, and management of the disease in older children and adults &lt;em&gt;[IC]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Patient education&lt;/strong&gt; should emphasize increasing knowledge of the disease process and active participation in treating asthma; &lt;em&gt;self-management is fundamental&lt;/em&gt; to successful therapy.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Structured education&lt;/span&gt;. A structured asthma education program should be considered &lt;em&gt;[IIB]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Triggers&lt;/span&gt;. Identify and avoid environmental triggers (including smoking &amp;amp; passive smoke) &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Monitoring. All patients should be able to identify signs and symptoms of active disease, and if indicated monitor peak expiratory flow rates (PEFR)&lt;/span&gt;. Patients with severe asthma and whose perception of their symptoms is poor, should measure their PEFR at home &lt;em&gt;[IID]&lt;/em&gt;, compare it to their personal best peak flow, and modify therapy or seek help as indicated &lt;em&gt;[IA]&lt;/em&gt;. For other patients, symptom monitoring may be sufficient and preferable to self-measuring PEFR &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Asthma Action Plan (AAP)&lt;/span&gt;. Provide an easy to understand written AAP to patients with persistent asthma &lt;em&gt;[IA]&lt;/em&gt;. An AAP is often useful for patients with intermittent asthma &lt;em&gt;[IID]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Type of asthma, initial severity and follow-up level of control determine asthma treatment&lt;/strong&gt;. Type: intermittent or persistent. If persistent, severity: mild, moderate, or severe. Level of control: well controlled, not well controlled, or very poorly controlled. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Drug therapy should focus on long-term suppressive therapy in persistent asthma&lt;/strong&gt;.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Anti-inflammatory agents&lt;/span&gt; (esp. inhaled corticosteroids) are the cornerstone of this approach &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Short-acting beta-agonists&lt;/span&gt; (SABAs) are for symptom based &quot;rescue&quot; &lt;em&gt;[IB]&lt;/em&gt;. Frequent use indicates poor disease control. The exception is planned use to prevent Exercise-Induced Bronchospasm. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Long-acting beta-agonists&lt;/span&gt; (LABAs) are used in combination with inhaled corticosteroids &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Special circumstances&lt;/strong&gt; addressed in the guideline include pregnancy and breast feeding, preparation for surgery, and complementary/alternative treatment. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;I = Generally should be performed&lt;/p&gt;&#xD;&#xA;&lt;p&gt;II = May be reasonable to perform&lt;/p&gt;&#xD;&#xA;&lt;p&gt;III = Generally should not be performed&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Conclusions were based on prospective randomized controlled trials (RCTs) if available, to the exclusion of other data; if randomized controlled trials (RCTs) were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Accurate diagnosis of asthma and appropriate management of patients with asthma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Delivery of high quality asthma care that includes asthma education, implementation of self management processes, and the use of asthma action plans &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise-induced bronchospasm will be decreased by short-acting beta agonists (SABAs) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Outcomes will be improved by inhaled corticosteroids. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A comprehensive program to reduce allergen exposure can improve outcomes. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Asthma Action Plans will improve clinical outcomes. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inhaled Short-Acting Beta Agonists (SABAs)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Several epidemiologic studies have found an association between excess use of beta2-agonist (short and long-acting) inhalers and asthma mortality. A causal relationship has not been demonstrated, and it is possible that beta2-agonists represent a mere marker for the severity of disease, being more frequently prescribed for patients with life-threatening asthma. If beta2-agonists do have a causative role, it may be an indirect one, such as delaying presentation until airway obstruction is more severe.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Inhaled Corticosteroids (ICSs)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Inhaled corticosteroids may have an adverse effect on linear growth (approximately 1 cm) in children. This effect must be balanced against the risk of poorly controlled asthma delaying growth. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Studies of markers of bone deposition and absorption, and of bone mineral density, suggest that osteopenia is a concern with inhaled corticosteroids in the adult population and increases with dose and duration of use. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk of cataracts increases with long-term use of inhaled corticosteroids. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;High doses of inhaled corticosteroids may cause systemic side effects (though to a much lesser extent than oral steroids). Risk of topical and systemic side effects with high-dose inhaled steroids can be minimized by having the patient rinse his/her mouth immediately after inhalation, spit out the rinse water, and by always using a spacer device, preferably with a valved holding chamber (VHC). The VHC also reduces the amount of inhaled corticosteroid from metered dose inhalers (MDIs) that can be swallowed and potentially available for systemic absorption. When the VHC with a mask is used, the facial area under the mask should be washed with mild soap and water after drug administration to prevent topical adverse effects. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Long-Acting Beta Agonists (LABAs)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A recent secondary data analysis associated use of LABAs with an increase in asthma deaths, though the numbers in the study were small and the interpretation is still a matter of controversy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients should be cautioned not to discontinue their established LABA without consulting their health care provider. (See original guideline document for guidance on proper use of LABAs.) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Leukotriene Receptor Antagonists (LTRAs)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Zafirlukast can potentiate warfarin and theophylline as well as interact with several other medications. Drug interactions with montelukast are rare. Post marketing surveillance of adverse effects reported with montelukast has been recently updated to include psychomotor hyperactivity (including irritability, agitation, aggressive behavior, restlessness, and tremor), and seizures. With regard to LTRAs, the Food and Drug Administration (FDA) states that &quot;healthcare professionals should consider discontinuing these medications if patients develop neuropsychiatric symptoms.&quot; Churg-Strauss vasculitis has rarely been reported in association with montelukast or zafirlukast in patients tapering chronic systemic corticosteroids.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Methylxanthines&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Potential drug interactions and clearance-altering co-morbidities (heart and liver disease, smoking, erythromycin, cimetidine and others) must be carefully screened with dosage adjustments as indicated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Systemic (Oral) Corticosteroids&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Systemic corticosteroids have numerous significant and undesirable long term side effects for both adults and children. Therefore, their long term use is undesirable and only recommended in the most severe cases. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chronic systemic corticosteroid therapy may be associated with obesity, moon facies, supraclavicular and nuchal fat pads, striae, easy bruisability, weakness, hypertension, osteopenia, and glucose intolerance. Children may also exhibit growth failure. Long-term (&amp;gt; 2 weeks) corticosteroid therapy may cause suppression of the hypothalamic-pituitary-adrenal axis. Systemic corticosteroid therapy can cause osteopenia and osteoporosis. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Pregnancy and Breastfeeding&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Systemic corticosteroid use in the first trimester is associated with cleft lip and palate, and later in pregnancy with pregnancy-induced hypertension and possibly preeclampsia. Theophylline in high doses is associated with adverse pregnancy outcomes; while usual doses are safe, unacceptable side effects are frequent. Few data are available about antileukotrienes in pregnancy. A recent trial suggests a slightly higher rate of major structural defects. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Zafirlukast's manufacturer has recommended against its use in breastfeeding because of reports of tumors in mice. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;See the original guideline document for additional information concerning asthma treatments and their side effects.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines should not be construed as including all proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Patient Resources" /><FieldValue Value="Pocket Guide/Reference Cards" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Resources" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;University of Michigan Health System. Asthma. Ann Arbor (MI): University of Michigan Health System; 2010 Mar. 25 p.  [2 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline was partially adapted from: National Asthma Education and Prevention Program. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Heart, Lung and Blood Institute, 2007.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It also uses material from the 2004 update for asthma in pregnancy, NIH Publication No. 05-5236.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="1996 Dec (revised 2010 Mar)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="University of Michigan Health System - Academic Institution" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;University of Michigan Health System&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Asthma Guideline Team&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Team Leader&lt;/em&gt;: Sean K Kesterson, MD, General Medicine&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Team Members&lt;/em&gt;: Joyce E Kaferle, MD, Family Medicine; Jill A Noble, MD, General Pediatrics; Manuel Arteta, MD, Pediatric Pulmonology; Alan P Baptist, MD, MPH, Allergy &amp;amp; Clinical Immunology; James A Freer, MD, Emergency Medicine; Cyril M Grum, MD, Pulmonary &amp;amp; Critical Care Medicine; Cary E Johnson, PharmD, College of Pharmacy; R Van Harrison, PhD, Medical Education&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;University of Michigan Medical Center (UMMC) Guidelines Oversight Team&lt;/em&gt;: Connie J Standiford, MD; William E Chavey, MD; R Van Harrison, PhD&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The University of Michigan Health System endorses the Guidelines of the Association of American Medical Colleges and the Standards of the Accreditation Council for Continuing Medical Education that the individuals who present educational activities disclose significant relationships with commercial companies whose products or services are discussed. Disclosure of a relationship is not intended to suggest bias in the information presented, but is made to provide readers with information that might be of potential importance to their evaluation of the information.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Team Member; Relationship; Company&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Manuel Arteta, MD (None)&lt;br /&gt;&#xD;&#xA;Alan P Baptist, MD (None) &lt;br /&gt;&#xD;&#xA;James A Freer, MD (None)&lt;br /&gt;&#xD;&#xA;Cyril M Grum MD (None)&lt;br /&gt;&#xD;&#xA;R Van Harrison, PhD (None)&lt;br /&gt;&#xD;&#xA;Cary E Johnson, PharmD (None)&lt;br /&gt;&#xD;&#xA;Joyce E Kaferle, MD (None)&lt;br /&gt;&#xD;&#xA;Sean K Kesterson, MD (None)&lt;br /&gt;&#xD;&#xA;Jill A Noble, MD (None)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: University of Michigan Health System. Asthma. Ann Arbor (MI): University of Michigan Health System; 2006 Feb. 16 p. [15 references]&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/asthma.html&quot; title=&quot;UMHS Web site&quot;&gt;University of Michigan Health System Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;One-page MQIC asthma. Michigan Quality Improvement Consortium guideline: general principles for the diagnosis and management of asthma MQIC guideline; 2008 Jul. 1p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/asthmamqic.pdf&quot; title=&quot;UMHS Web site&quot;&gt;University of Michigan Health System (UMHS) Web Site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One-page MQIC Asthma Ages 0-4. Michigan Quality Improvement Consortium Guideline Management of asthma in children 0 to 4 years; 2008 Jul. 1 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/mqic0to4.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One-page MQIC Asthma Ages 5-11. Michigan Quality Improvement Consortium Guideline Management of asthma in children 5 to 11 years; 2008 Jul. 1 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/mqic5to11.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One-page MQIC Asthma Ages 12 &amp;amp; Up. Michigan Quality Improvement Consortium Guideline Management of asthma in youth 12 years and older and adults; 2008 Jul. 1 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/mqic12up.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Asthma medication card. University of Michigan Health Systems; 2010 Jan. 5 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/asthma/asthmacard.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;EPR-3 pocket guide. University of Michigan Health Systems; 2008 Jun 30. 2 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/EPR-3_pocket_guide.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;AeroChamber mask size guide. 1999 May. 1p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/facemask.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Predicted average peak expiratory flow. 1963. 1 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/pefrates.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web Site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, Continuing Medical Education (CME) information is available from the &lt;a href=&quot;http://cme.med.umich.edu/iCME/asthma10/default.asp&quot; title=&quot;UMHS web site&quot;&gt;UMHS Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Asthma action plan for patients 0-4 years. University of Michigan Health System; 2009. 1 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/action0to4.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Asthma action plan for patients 5-11 years. University of Michigan Health System; 2009. 1 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/action5to11.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Asthma action plan for patients 12 years or older. University of Michigan Health System; 2009. 1 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/action12andolder.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlling your asthma: patient education guide. American College of Chest Physicians; 2004. 32 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/chestpt.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt; and a Spanish version: &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/chestspanish.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;What you need to know about asthma. University of Michigan Health System; 2010. 3 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/asthma.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Learning about asthma. University of Michigan Health System; 2006. 30 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/learning.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Using your Diskus&amp;reg;. Patient education guide. American College of Chest Physicians; 2006. 16 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/various.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Steps for the correct use of your metered dose inhaler (MDI). University of Michigan Health System; 2010. 1 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/mdi.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;How to use your valved holding chamber. University of Michigan Health System; 2009. 1 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/ValvedHoldingChamber.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;How to use your valved holding chamber with mask. University of Michigan Health System; 2010. 1 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/ValvedHoldingChamberMask.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MDI dose tracking record. University of Michigan Health System; 2010. 1 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/MDItracking.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;How to give nebulized medicines. University of Michigan Health System; 2010. 1 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/nebulized.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;How to use your peak flow meter. University of Michigan Health System; 2010. 1 p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/FHP/practiceguides/asthma/peakflow.pdf&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on August 21, 2000. The information was verified by the guideline developer on November 22, 2000. This NGC summary was updated on November 8, 2004. The updated information was verified by the guideline developer on December 7, 2004. This summary was updated by ECRI on December 5, 2005 following the U.S. Food and Drug Administration (FDA) advisory on long-acting beta2-adrenergic agonists (LABA). This NGC summary was updated by ECRI on February 23, 2006. The updated information was verified by the guideline developer on March 17, 2006. This summary was updated by ECRI Institute on May 14, 2010 following the U.S. Food and Drug Administration (FDA) advisory on Long-Acting Beta-Agonists (LABAs). This NGC summary was updated by ECRI Institute on September 1, 2010. The updated information was verified by the guideline developer on October 1, 2010.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is copyrighted by the University of Michigan Health System (UMHS).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
